Table S1. Clinical and dosimetric variable associations with gender.

Characteristic	All patients			Female			Male		P value
	No.	%		No.	%		No.	%
Total No. of patients	108	100.0		58	54		50	46	–
Age									0.17
<67 years	53	49		32	55		21	42
≥67 years	55	51		26	45		29	58
Race									0.53
Caucasian	57	53		29	50		28	56
Other	51	47		29	50		22	44
Smoking status									0.79
Current smoker	25	23		14	24		11	22
Non-current smoker	83	77		44	76		39	78
ECOG PS									0.36
0	32	30		15	26		17	34
1–2	76	70		43	74		33	66
CCI									0.24
0–1	71	66		41	71		30	60
2+	37	34		17	29		20	40
Pre-existing diabetes									0.02
Yes	24	22		8	14		16	32
No	84	78		50	86		34	68
Pre-existing cardiac disease									0.49
Yes	29	27		14	24		15	30
No	79	73		44	76		35	70
Pre-existing lung disease									0.55
Yes	53	49		30	52		23	46
No	55	51		28	48		27	54
Relapse									0.86
Yes	55	51		30	52		25	50
No	53	49		28	48		25	50
Gross tumor volume									0.08
<98.6 cm3	55	51		34	59		21	42
≥98.6 cm3	53	49		24	41		29	58
Tumor location									0.06
Pericardial	60	56		37	64		23	46
Non-pericardial	48	44		21	36		27	54
Treatment length									0.61
<45 days	49	45		25	43		24	48
≥45 days	59	55		33	57		26	52
Treatment break									0.77
Yes	14	13		7	12		7	14
No	94	87		51	88		43	86
Mean heart dose									0.01
<13.1 Gy	53	49		22	38		31	62
≥13.1 Gy	55	51		36	62		19	38
Heart V5									0.18
<49.4%	53	49		25	43		28	56
≥49.4%	55	51		33	57		22	44
Heart V10									0.18
<39.4%	53	49		25	43		28	56
≥39.4%	55	51		33	57		22	44
Heart V15									0.08
<31.0%	53	49		24	41		29	58
≥31.0%	55	51		34	59		21	42
Heart V20									0.01
<22.7%	53	49		22	38		31	62
≥22.7%	55	51		36	62		19	38
Heart V25									0.01
<18.3%	53	49		22	38		31	62
≥18.3%	55	51		36	62		19	38
Heart V30									0.03
<15.6%	53	49		23	40		30	60
≥15.6%	55	51		35	60		20	40
Heart V35									0.01
<11.8%	53	49		22	38		31	62
≥11.8%	55	51		36	62		19	38
Heart V40									0.01
<9.1%	53	49		22	38		31	62
≥9.1%	55	51		36	62		19	38
Heart V45									0.03
<6.8%	53	49		23	40		30	60
≥6.8%	55	51		35	60		20	40
Heart V50									0.03
<5.3%	53	49		23	40		30	60
≥5.3%	55	51		35	60		20	40
Heart V55
<3.5%	54	50		24	41		30	60	0.05
≥3.5%	54	50		34	59		20	40
Heart V60									0.25
<1.9%	54	50		26	45		28	56
≥1.9%	54	50		32	55		22	44
Mean lung dose									0.57
<19.1 Gy	55	51		31	53		24	48
≥19.1 Gy	53	49		27	47		26	52
Lung V5									0.34
<59.8%	55	51		32	55		23	46
≥59.8%	53	49		26	45		27	54
Lung V20									0.84
<32.0%	55	51		29	50		26	52
≥32.0%	53	49		29	50		24	48

ECOG PS, Eastern Cooperative Oncology Group performance status; CCI, Charlson comorbidity index.